S100A10 Knockdown通过调节线粒体氧化酸化来加剧烯诱导的心肌细胞缩
Feixue Xu1,2, Yajie Chen1,2, Man Xu1,2
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Frontiers in genetics
|November 6, 2025
概括
蛋白质S100A10对于维持心脏细胞中的线粒体功能至关重要. 它的下调会通过损害线粒体呼吸和ATP产生来恶化心脏缩,这表明S100A10是治疗点.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 线粒体生物学 线粒体生物学
背景情况:
- 线粒体功能障碍是心脏缩的一个关键特征.
- 一种结合的蛋白质S100A10会影响mTOR信号传递和线粒体功能.
- 需要阐明S100A10在烯诱导的心肌细胞缩中的精确作用.
研究的目的:
- 为了研究S100A10在烯 (PE) 诱导的心肌细胞缩中的作用.
- 在这种情况下,探索S100A10功能的机械基础.
- 确定S100A10对线粒体功能和mTOR信号传递的影响.
主要方法:
- 烯 (PE) 用于诱导初级新生儿大鼠心肌细胞 (NRCMs) 的过度缩小.
- 使用siRNA降低S100A10的调节,并通过共免疫沉评估其与ANXA2的相互作用.
- 西方涂抹分析了mTOR通路激活;通过电子运输链复杂表达,线粒体膜潜力 (JC-1) 和氧化应激 (MitoSOX) 来评估线粒体功能.
主要成果:
- S100A10表达在过度缩的小鼠心脏中升高.
- 发现S100A10与ANXA2相互作用,激活mTOR/4E-BP信号通路.
- 在NRCM中S100A10的淘汰导致线粒体呼吸链蛋白减少,氧化酸化受损,线粒体膜潜能降低,ATP产量降低.
结论:
- 降低S100A10的调节会加剧PE诱导的心肌细胞缩.
- 在调节线粒体呼吸链蛋白水平方面,S100A10发挥着新的作用,可能通过mTOR/4E-BP通路.
- 这些发现为开发心脏缩的新治疗策略提供了潜在的理论基础.
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
01:29Cardiomyopathy V: Interprofessional Care
323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323